Sijmen de Vries, Pharming CEO
September 28, 2022 06:44 AM EDT
FDA+

For­mer No­var­tis drug for ul­tra-rare dis­ease gets speedy FDA re­view

Amber Tong

Three years af­ter pay­ing a mod­est $20 mil­lion up­front to grab a late-stage rare dis­ease drug from No­var­tis, Pharm­ing has lined up a pri­or­i­ty re­view …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times